Target family: Somatostatin receptors (type: gpcr)
Target: SST<sub>5</sub> receptor

Ligand: AC-178,335 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pKi
Reference (Journal): A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats.
Published in: Mol Pharmacol

Ligand: BIM 23023 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: BIM 23023 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23023 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23030 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: BIM 23030 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: BIM 23050 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: BIM 23052 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: BIM 23052 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: BIM 23052 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: BIM 23052 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23052 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23056 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: BIM 23056 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: BIM 23056 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23056 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: BIM 23056 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: BIM 23056 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23056 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi

Ligand: BIM 23056 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: BIM 23059 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.600000381469727 pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: BIM 23060 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: BIM 23197 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
Published in: J Clin Invest

Ligand: BIM 23268 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23268 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23313 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23313 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.600000381469727 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BIM 23454 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pIC50
Reference (Journal): Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment.
Published in: Endocrinology

Ligand: BIM 23627 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment.
Published in: Endocrinology

Ligand: BOC-ATE (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Published in: Clin Cancer Res

Ligand: CGP 23996 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: CGP 23996 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: CGP 23996 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: CGP 23996 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: cortistatin-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: cortistatin-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: cortistatin-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: cortistatin-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: CST-17 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: CST-17 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: CST-17 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Superagonism at the human somatostatin receptor subtype 4.
Published in: J Pharmacol Exp Ther

Ligand: CST-17 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: Des-AA5-[D-Trp8]SRIF (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan.
Published in: J Med Chem

Ligand: [D-Tyr8]CYN 154806 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: [D-Tyr8]CYN 154806 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: KE 108 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pIC50
Reference (Journal): A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors.
Published in: Eur J Pharmacol

Ligand: L-362,855 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: L-362,855 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: L-362,855 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: L-362,855 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: L-362,855 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-362,855 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-363,301 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-363,301 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-363,301 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: L-817,818 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry.
Published in: Science

Ligand: lanreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2001), FDA (2007)
Primary target: yes
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: lanreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2001), FDA (2007)
Primary target: yes
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: lanreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2001), FDA (2007)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: lanreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2001), FDA (2007)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: lanreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2001), FDA (2007)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Binding properties of somatostatin receptor subtypes.
Published in: Metab Clin Exp

Ligand: lanreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2001), FDA (2007)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: lanreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2001), FDA (2007)
Primary target: no
Median affinity: 7.599999904632568 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: [L-Tyr8]CYN 154806 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: [L-Tyr8]CYN 154806 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: NOC-ATE (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Published in: Clin Cancer Res

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Primary target: no
Median affinity: 7.800000190734863 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Median affinity:  pKi
Reference (Journal): Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.
Published in: Proc Natl Acad Sci USA

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Median affinity:  pKi
Reference (Journal): Binding properties of somatostatin receptor subtypes.
Published in: Metab Clin Exp

Ligand: octreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988), EMA (2022)
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: pasireotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: yes
Median affinity: 9.800000190734863 pIC50
Reference (Journal): Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
Published in: Neuroendocrinology

Ligand: PRL-2915 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pKi
Reference (Journal): Highly potent cyclic disulfide antagonists of somatostatin.
Published in: J Med Chem

Ligand: PRL-2970 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKi
Reference (Journal): Highly potent cyclic disulfide antagonists of somatostatin.
Published in: J Med Chem

Ligand: S5A1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.270000457763672 pKi
Reference (Journal): Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5.
Published in: Endocrinology

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding properties of somatostatin receptor subtypes.
Published in: Metab Clin Exp

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: seglitide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.
Published in: Proc Natl Acad Sci USA

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Binding properties of somatostatin receptor subtypes.
Published in: Metab Clin Exp

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.
Published in: Proc Natl Acad Sci USA

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry.
Published in: Science

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity.
Published in: J Med Chem

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Superagonism at the human somatostatin receptor subtype 4.
Published in: J Pharmacol Exp Ther

Ligand: SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Binding properties of somatostatin receptor subtypes.
Published in: Metab Clin Exp

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Superagonism at the human somatostatin receptor subtype 4.
Published in: J Pharmacol Exp Ther

Ligand: [111In]DOTA-BOC-ATE (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.4 pIC50
Reference (Journal): Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Published in: Clin Cancer Res

Ligand: [111In]DOTA-NOC (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Published in: Eur J Nucl Med Mol Imaging

Ligand: [111In]DOTA-NOC-ATE (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.4 pIC50
Reference (Journal): Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Published in: Clin Cancer Res

Ligand: [111In,90Y]DOTA-LAN (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Published in: Eur J Nucl Med Mol Imaging

Ligand: [111In,90Y]DOTA-NOC (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Published in: Eur J Nucl Med Mol Imaging

Ligand: [111In,90Y]DOTA-OC (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.199999809265137 pIC50
Reference (Journal): DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Published in: Eur J Nucl Med Mol Imaging

Ligand: [111In,90Y]DOTA-TOC (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.7 pIC50
Reference (Journal): DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Published in: Eur J Nucl Med Mol Imaging

Ligand: [125I]CGP 23996 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.800000190734863 pKd
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: [125I]CGP 23996 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.5 pKd
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [125I]CGP 23996 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.5 pKd
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: [125I]LTT-SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.5 pKd
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [125I]LTT-SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry.
Published in: Science

Ligand: [125I]LTT-SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.5 pKd
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [125I]LTT-SRIF-28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 11 pKd
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: [125I]Tyr10-CST14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.2 pKd
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: [125I]Tyr10-CST14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.3 pKd
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [125I]Tyr10-CST14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.3 pKd
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [125I]Tyr11-SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10 pKd
Reference (Journal): Characterization of cloned human somatostatin receptor SSTR5.
Published in: Mol Pharmacol

Ligand: [125I]Tyr11-SRIF-14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10 pKd
Reference (Journal): Characterization of cloned human somatostatin receptor SSTR5.
Published in: Mol Pharmacol

Ligand: [125I]Tyr3 SMS 201-995 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.640000343322754 pKd
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: [125I]Tyr3 SMS 201-995 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.640000343322754 pKd
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [125I]Tyr3 SMS 201-995 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKd
Reference (Journal): Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Published in: Neuropharmacology

Ligand: vapreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: no
Median affinity: 8.199999809265137 pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: vapreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Binding properties of somatostatin receptor subtypes.
Published in: Metab Clin Exp

Ligand: vapreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): The elucidation of somatostatin receptor functions: a current view.
Published in: Rev Physiol Biochem Pharmacol

Ligand: vapreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Published in: Endocrinology

Ligand: vapreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): [125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: vapreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Published in: Eur J Pharmacol

Ligand: vapreotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: veldoreotide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.
Published in: Endocrinology

Ligand: zavolosotine (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9 pEC50
Reference (Patent): Somatostatin receptor type 5 agonist for the treatment of hyperinsulinism